EXXELERATE: a negative trial with importance for clinical practice

Affiliations

¹ Department of Rheumatology, Diakonhjemmet Hospital, Oslo, NO-0319 Norway. Electronic address: t.k.kvien@medisin.uio.no.
² Department of Rheumatology, Diakonhjemmet Hospital, Oslo, NO-0319 Norway.

Comment

Tore K Kvien et al. Lancet. 2016.

. 2016 Dec 3;388(10061):2718-2719.

doi: 10.1016/S0140-6736(16)31923-7. Epub 2016 Nov 15.

¹ Department of Rheumatology, Diakonhjemmet Hospital, Oslo, NO-0319 Norway. Electronic address: t.k.kvien@medisin.uio.no.
² Department of Rheumatology, Diakonhjemmet Hospital, Oslo, NO-0319 Norway.

No abstract available

Comment on

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R. Smolen JS, et al. Lancet. 2016 Dec 3;388(10061):2763-2774. doi: 10.1016/S0140-6736(16)31651-8. Epub 2016 Nov 15. Lancet. 2016. PMID: 27863807 Clinical Trial.